Key result
Peptide-derived antibodies against coxsackievirus VP1, VP2, and VP3 demonstrated cross-reactivity to human enterovirus B, with NO5 detecting less than 1 microg of viruses.
Population
Human enterovirus B (coxsackievirus group B) viral capsid proteins (VP1, VP2, VP3)
Comparison
Seven peptide-derived antibodies directed… vs Commercial VP1 monoclonal antibody (MAb)
Design
Preclinical
Authors
Loading...
Should not yet inform clinical diagnostics; hypothesis-generating for cross-reactive peptide reagents in enterovirus B.
The development of cross-reactive peptide antibodies against human enterovirus B capsid proteins provides potential new diagnostic reagents with high sensitivity.
Jeong et al. (2007) studied Human enterovirus B / Coxsackievirus group B. Peptide-derived antibodies against coxsackievirus VP1, VP2, and VP3 vs. Commercial VP1 monoclonal antibody (MAb) was evaluated on Sensitivity and reactivity of antibodies. Peptide-derived antibodies against coxsackievirus VP1, VP2, and VP3 demonstrated cross-reactivity to human enterovirus B, with NO5 detecting less than 1 microg of viruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: